Anti-carbamylated protein antibodies in systemic sclerosis.
Anti-carbamylated protein antibodies
Skin involvement
Systemic sclerosis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
21 07 2023
21 07 2023
Historique:
received:
25
02
2023
accepted:
25
06
2023
medline:
24
7
2023
pubmed:
22
7
2023
entrez:
21
7
2023
Statut:
epublish
Résumé
To investigate the presence of different isotypes of anti-carbamylated protein (CarP) antibodies in systemic sclerosis (SSc) patients and its association with skin involvement. Sera of 194 SSc patients from the Leiden CCISS cohort, fulfilling ACR/EULAR 2013 criteria and a clinical diagnosis of SSc, 83 patients with other connective tissue diseases/Raynaud's Phenomenon, 24 rheumatoid arthritis patients and 98 age and sex-matched healthy controls were tested for the presence of anti-CarP IgG, IgA and IgM, determined by ELISA. Clinical characteristics, that were evaluated in SSc patients, included age, anti-topoisomerase antibodies (ATA), anti-centromere antibodies (ACA) and modified Rodnan Skin Score (mRSS). The SSc patients were 55 (SD:13) years and 155 (80%) were female. Forty-four (23%) patients tested positive for ATA, and 80 (42%) ACA. The median mRSS was 2 (range: 0; 47). Prevalence of anti-CarP IgG was higher in SSc patients than in healthy controls (8% vs 3%, p = 0.007. Prevalence of anti-CarP IgA and IgM and levels of anti-CarP isotypes were comparable between SSc patients and healthy controls. Fifteen (8%) SSc patients tested positive for anti-CarP IgG, 16 (8%) for anti-CarP IgA, and 36 (19%) for anti-CarP IgM. There were no significant correlations between age and levels of anti-CarP isotypes. No correlation between anti-CarP IgG levels and mRSS was found (r = 0.141, p = 0.049), nor for anti-CarP IgM and IgA levels. Anti-CarP IgA levels were higher in ATA compared to ACA positive SSc patients (ATA: 616 aU/ml [359; 1103]; ACA: 424 aU/ml [300; 673], p = 0.015). SSc patients can test positive for Anti-CarP IgG, IgA and IgM. We do not observe a relevant clinical association between anti-CarP antibody response and skin involvement in SSc.
Sections du résumé
BACKGROUND
To investigate the presence of different isotypes of anti-carbamylated protein (CarP) antibodies in systemic sclerosis (SSc) patients and its association with skin involvement.
METHODS
Sera of 194 SSc patients from the Leiden CCISS cohort, fulfilling ACR/EULAR 2013 criteria and a clinical diagnosis of SSc, 83 patients with other connective tissue diseases/Raynaud's Phenomenon, 24 rheumatoid arthritis patients and 98 age and sex-matched healthy controls were tested for the presence of anti-CarP IgG, IgA and IgM, determined by ELISA. Clinical characteristics, that were evaluated in SSc patients, included age, anti-topoisomerase antibodies (ATA), anti-centromere antibodies (ACA) and modified Rodnan Skin Score (mRSS).
RESULTS
The SSc patients were 55 (SD:13) years and 155 (80%) were female. Forty-four (23%) patients tested positive for ATA, and 80 (42%) ACA. The median mRSS was 2 (range: 0; 47). Prevalence of anti-CarP IgG was higher in SSc patients than in healthy controls (8% vs 3%, p = 0.007. Prevalence of anti-CarP IgA and IgM and levels of anti-CarP isotypes were comparable between SSc patients and healthy controls. Fifteen (8%) SSc patients tested positive for anti-CarP IgG, 16 (8%) for anti-CarP IgA, and 36 (19%) for anti-CarP IgM. There were no significant correlations between age and levels of anti-CarP isotypes. No correlation between anti-CarP IgG levels and mRSS was found (r = 0.141, p = 0.049), nor for anti-CarP IgM and IgA levels. Anti-CarP IgA levels were higher in ATA compared to ACA positive SSc patients (ATA: 616 aU/ml [359; 1103]; ACA: 424 aU/ml [300; 673], p = 0.015).
CONCLUSION
SSc patients can test positive for Anti-CarP IgG, IgA and IgM. We do not observe a relevant clinical association between anti-CarP antibody response and skin involvement in SSc.
Identifiants
pubmed: 37480150
doi: 10.1186/s13075-023-03099-3
pii: 10.1186/s13075-023-03099-3
pmc: PMC10360323
doi:
Substances chimiques
Antibodies, Antinuclear
0
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Informations de copyright
© 2023. The Author(s).
Références
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Ann Rheum Dis. 2016 Jun;75(6):1139-44
pubmed: 26443608
Nat Rev Rheumatol. 2010 Feb;6(2):112-6
pubmed: 20125179
Ann Rheum Dis. 2003 Sep;62(9):904-5
pubmed: 12922969
PLoS One. 2018 Dec 31;13(12):e0210023
pubmed: 30596753
J Rheumatol. 2005 Sep;32(9):1643-9
pubmed: 16142854
Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17372-7
pubmed: 21987802
Immunol Res. 2015 Feb;61(1-2):24-30
pubmed: 25391608
Semin Arthritis Rheum. 2005 Aug;35(1):35-42
pubmed: 16084222
J Rheumatol. 2001 Jul;28(7):1573-6
pubmed: 11469464
RMD Open. 2016 Mar 15;2(1):e000159
pubmed: 27042333
Ann Rheum Dis. 2007 Jun;66(6):754-63
pubmed: 17234652
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Arthritis Res Ther. 2016 Nov 25;18(1):276
pubmed: 27887639